Flavored E-Cigarette Bans Reduce Youth Vaping but Slow Decline in Cigarette Smoking
By
PaulHoule
The kind of bagel that ruins lesser bagels for you.
Summary
A study by Mass General Brigham found that flavored e-cigarette bans significantly reduced vaping among young adults and adults in states with such policies, though the decline in cigarette smoking was slower.
Key quotes
· 2 pulledInvestigators found that e-cigarette use significantly declined among young adults and adults in states that had enacted flavor bans relative to states that did not.
A new study by investigators from Mass General Brigham examined the effects of policies banning flavored e-cigarettes on adults and young people.
You might also wanna read
Columbia University Study Introduces 'Shooting-Free Days' Metric to Track Gun Violence Prevention in U.S. Cities
A new study from Columbia University researchers introduces 'shooting-free days' (SFD) as a novel metric for tracking gun violence preventio
publichealth.columbia.edu·2mo ago
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·1h ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·2h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·5h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·6h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h ago